Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Leukemia 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) 1

Interventions

pembrolizumab 51Carboplatin 21Paclitaxel 20Cyclophosphamide 18Nivolumab 13Taxes 10130-nm albumin-bound paclitaxel 10olaparib 9Specimen Handling 9spartalizumab 8fludarabine 8Doxorubicin 8durvalumab 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Cisplatin 7Biopsy 7veliparib 6atezolizumab 6Fulvestrant 6Albumin-Bound Paclitaxel 6liposomal doxorubicin 5eribulin 5budigalimab 5Irinotecan 5Ipilimumab 5aldesleukin 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × Bexarotene × Clear all
NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡